Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy.

The vedolizumab group (n = 15) showed a significant increase ( P = 0.007) despite greater variability in baseline concentrations, while the anti-TNF group (n = 14) demonstrated a more uniform response pattern with highly significant increases ( P < 0.0001).

also in 132,142 other papers

VZV-specific CMI responses increased after vaccination, although the difference did not reach statistical significance (prevaccine [n = 18] median 33 cells/million, interquartile range [IQR] 11–73 vs postvaccine [n = 24] median 56 cells/million, IQR 21–102; P = 0.13).

also in 111,027 other papers